GlobalData
GlobalData

shankar besta

  • Home
  • Author: shankar besta

Immuno-oncology agents to continue transforming cancer treatment landscape, says GlobalData

Immuno-oncology (IO) agents have transformed the oncology landscape in the last decade, particularly immune checkpoint inhibitors (ICIs) in solid tumor settings and chimeric antigen receptor (CAR) T-cells in hematological malignancies, with patients who previously had very limited therapeutic options achieving long term remissions and even cure. Continued investment into IO R&D in both academia and […]
Read more

Mine-site investment in safety-related technologies rising, says GlobalData

High levels of investment are being made in areas such as mine planning and management software, mine communication, and predictive maintenance, with increasing levels of investment in safety-related technologies that include drones, collision avoidance, and fatigue detection, according to the latest global mine-site technology adoption survey by GlobalData, a leading data and analytics company. The […]
Read more

India to dominate upcoming trunk/transmission pipeline length additions in Asia by 2027, says GlobalData

India is set to dominate the trunk/transmission pipeline length additions for planned and announced projects in Asia between 2023 and 2027, contributing around 46% of the region’s total planned and announced pipeline additions by 2027, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Oil and Gas Pipelines Length and Capital Expenditure […]
Read more

National Lipid Day a timely reminder of dyslipidemia, says GlobalData

National Lipid Day, observed on 10 May every year creates awareness of dyslipidaemia, says GlobalData, a leading data and analytics company. Dr Shireen Mohammad, Cardiovascular & Metabolic Disorders Analyst at GlobalData, comments: “An unmet need in the dyslipidemia space is patient education and National Lipid Day is a great way to raise awareness for this […]
Read more

GlobalData forecasts Immunogen’s Elahere sales to reach $615 million by 2029

US-based Immunogen recently announced positive top-line data from their Phase III MIRASOL trial evaluating Elahere (mirvetuximab) for the treatment of platinum-resistant ovarian cancer. The company plans to use the data to support their forthcoming supplemental Biologics Licensing Application for full FDA approval. Elahere’s sales are expected to reach $615 million by 2029, registering a 114% […]
Read more

Take-Two to release earnings on May 17: Will analyst sentiment continue to rise from 11% increase in previous earnings call?

Take-Two Interactive Software Inc (Take-Two) is scheduled to release its earnings on 17 May 2023. Analyst sentiment was up 11% in Q1 2023 over Q4 2022 with optimism around the Zynga acquisition, cost reduction initiatives, and digital net bookings, according to GlobalData, a leading data and analytics company. Gain a comprehensive understanding of Take-Two with […]
Read more
1 113 114 115 116 117 136